Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine (Mindful Diagnostics and Therapeutics, LLC)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tdap is a combination vaccine composed of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis antigens. While traditionally used for active immunization against tetanus, diphtheria, and pertussis, it is being investigated by Mindful Diagnostics and Therapeutics, LLC in the 'Tdap PANDA' pilot study for its potential impact on Alzheimer's disease. The research explores whether Tdap vaccination can influence plasma-based Alzheimer's biomarkers, including amyloid-beta, tau, and neurofilament light protein (NfL), as well as various immune parameters. This repurposing effort is driven by epidemiological data suggesting that certain adult vaccinations are associated with a reduced risk of developing dementia. The study specifically targets adults aged 50 to 80 who are out of compliance for their standard Tdap booster.
- Other names
- Tdap vaccineTetanus-diphtheria-acellular pertussis vaccine
02
Targets
PRN (Pertactin)BCR (Immunoglobulin G B Cell Receptor)P fimbriaeDiphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine (Mindful Diagnostics and Therapeutics, LLC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine (Mindful Diagnostics and Therapeutics, LLC).